# US 2023/0272376 A1 · Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272376 A1
- Document ID: US20230272376A1
- Status: Published application
- Kind: A1
- Application number: 17/985,970
- Filed: 2022-11-14
- Published: 2023-08-31
- Earliest claimed: 2020-05-15
- Assignees: Korro Bio, Inc.
- Applicants: Korro Bio, Inc.
- Inventors: Matthew Jarpe; Mallikarjuna Reddy Putta; Andrew Fraley
- Web page: https://patentgrep.com/patent/US20230272376A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/323: modified ring structure
- C12N 2310/332: Abasic residue
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/34: Allele or polymorphism specific uses
- C12N 2800/107: for mammalian
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to methods and compositions for editing a MECP2 polynucleotide, e.g., a MECP2 polynucleotide comprising a SNP associated with Rett syndrome. The invention also relates to methods and compositions for treating or preventing Rett syndrome in a subject.

## Claims

### Claim 1

A method of editing a MECP2 polynucleotide comprising a single nucleotide polymorphism (SNP) associated with Rett syndrome, the method comprising contacting the MECP2 polynucleotide with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, thereby editing the MECP2 polynucleotide.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell endogenously expresses ADAR.

### Claim at position 4

4-9. (canceled)

### Claim 10

A method of treating Rett syndrome in a subject in need thereof, the method comprising
contacting the MECP2 polynucleotide in a cell of the subject with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, thereby treating the subject.

### Claim 11

A method of treating Rett syndrome in a subject in need thereof, the method comprising
contacting the MECP2 polynucleotide in a cell with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, and
administering the cell to the subject, thereby treating the subject.

### Claim at position 7

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the guide oligonucleotide comprises a nucleic acid sequence complementary to a MECP2 mRNA sequence comprising the SNP associated with Rett syndrome.

### Claim 15 (depends on 1)

The method of claim 1, wherein the oligonucleotide further comprises one or more adenosine deaminase acting on RNA (ADAR)-recruiting domains.

### Claim 16 (depends on 1)

The method of claim 1, wherein the MECP2 polynucleotide encodes a MECP2 protein comprising a pathogenic amino acid comprising a premature stop codon at positions 255, 168, 294 and/or 270, resulting from the SNP.

### Claim 17 (depends on 16)

The method of claim 16, wherein the adenosine to inosine alteration substitutes the pathogenic amino acid with a wild type amino acid, wherein the wild type amino acid at positions 255, 168, 294 and/or 270 is an arginine.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the guide oligonucleotide comprises the structure:
[Am]-X1-X2-X3—[Bn]
wherein each of A and B is a nucleotide;
m and n are each, independently, an integer from 5 to 40;
X1, X2, and X3 are each, independently, a nucleotide, wherein at least one of X1, X2, or X3 is an alternative nucleotide.

### Claim 20 (depends on 1)

The method of claim 1, wherein the guide oligonucleotide comprises the structure:
[Am]-X1-X2-X3—[Bn]
wherein each of A and B is a nucleotide;
m and n are each, independently, an integer from 5 to 40;
X1, X2, and X3 are each, independently, a nucleotide, wherein at least one of X1, X2, or X3 has the structure of any one of Formula I-I:
wherein N1 is hydrogen or a nucleobase;
R1 is hydroxy, halogen, or C1-C6 alkoxy;
R2 is hydrogen, hydroxy, halogen, or C1-C6 alkoxy; and
R3 is hydrogen, hydroxy, halogen, or C1-C6 alkoxy.

### Claim at position 15

21-27. (canceled)

### Claim 28 (depends on 20)

The method of claim 20, wherein at least one of X1, X2, and X3 has the structure of Formula I, wherein R1 is fluoro, hydroxy, or O-methyl, and N1 is a nucleobase.

### Claim at position 17

29-102. (canceled)

### Claim 103 (depends on 1)

The method of claim 1, wherein the guide oligonucleotide comprises the structure:
[Am]-X1-X2-X3—[Bn]
wherein each of A and B is a nucleotide;
m and n are each, independently, an integer from 5 to 40;
X1, X2, and X3 are each, independently, a nucleotide, wherein at least one of X1, X2, and X3 has the structure of any one of Formula XII-XV:
wherein N1 is hydrogen or a nucleobase;
R6 is hydrogen, hydroxy, or halogen;
R7 is hydrogen, hydroxy, halogen, or C1-C6 alkoxy;
R8 is hydrogen or halogen;
R9 is hydrogen or hydroxy, halogen, or C1-C6 alkoxy;
R10 Is hydrogen or halogen; and
R11 is hydrogen or hydroxy, halogen, or C1-C6 alkoxy.

### Claim at position 19

104-106. (canceled)

### Claim 107 (depends on 103)

The method of claim 103, wherein at least one of X1, X2, and X3 has the structure of Formula XIII, in which each of R8 and R9 is hydrogen.

### Claim at position 21

108-128. (canceled)

### Claim 129 (depends on 19)

The method of claim 19, wherein each of [Am] and [Bn] comprises at least four terminal phosphorothioate linkages.

### Claim at position 23

130-137. (canceled)

### Claim 138 (depends on 19)

The method of claim 19, wherein at least 20% of the nucleotides of [Am] and [Bn] combined are 2′-O-methyl-nucleotides.

### Claim at position 25

139-144. (canceled)

### Claim 145 (depends on 20)

The method of claim 20, wherein at least one of X1, X2, and X3 has the structure of Formula I, wherein R1 is fluoro, hydroxy, or methoxy and N1 is a nucleobase each of X1, X2, and X3 that does not have the structure of Formula I is a ribonucleotide; [Am] and [Bn] each comprise at least five terminal 2′-O-methyl-nucleotides and at least four terminal phosphorothioate linkages; and at least 20% of the nucleotides of [Am] and [Bn] combined are 2′-O-methyl-nucleotides.

### Claim 146

(canceled)

### Claim 147 (depends on 103)

The method of claim 103, wherein at least of X1, X2, and X3 has the structure of Formula XIII, wherein R8 and R9 are each hydrogen, and each of X1, X2 and X3 that does not have the structure of Formula XII is a ribonucleotide; [Am] and [Bn] each include at least five terminal 2′-O-methyl-nucleotides and at least four terminal phosphorothioate linkages; and at least 20% of the nucleotides of [Am] and [Bn] combined are 2′-O-methyl-nucleotides.
